ImmunoGuide® Enzyme immunoassay (ELISA) for the semi-quantitative determination of free antibodies to Certolizumab pegol (CZP) in serum and plasma.<br><br>
The drug Certolizumab pegol (trade name Cimzia®) is a tumor necrosis factor alpha (TNFα) blocker and binds to human TNFα with a KD of 90pM. Certolizumab pegol is a recombinant, humanized antibody Fab' fragment, with specificity for TNFα, conjugated to an approximately 40kDa polyethylene glycol (PEG). The Fab' fragment is manufactured in E. coli and is subsequently subjected to purification and conjugation to PEG2MAL40K, to generate Certolizumab pegol.<br><br>
The ImmunoGuide Antibody to Certolizumab pegol ELISA kit has been designed for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 1 hour (RT) + 30 min. (RT) + 15 min. (RT) = 2 hour, 45 min. total incubation time
- Catalog number:
- TM09035
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- Positive control
- design:
- Enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Cimzia®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- Standards:
- 5 Standards, ready to use
- Standard range:
- 0 / 30 - 1000 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 40 ng/mL
- Species:
- Human
- Products related:
- Additional info:
